Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2016-01-18 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
第八届董事会第四十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at a board meeting of Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. It details decisions on external investments, repurchase and cancellation of restricted shares, changes in registered capital and amendments to the articles of association, and the unlocking of restricted stock under an incentive plan. The document includes voting results and references to other announcements for detailed information. It does not contain full financial statements or comprehensive financial analysis. The content focuses on board decisions and management actions rather than financial reporting or regulatory filings. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the company's board or senior management.
2016-01-18 Chinese
关于回购注销部分股权激励股份减少注册资本的债权人公告
Share Issue/Capital Change Classification · 95% confidence The document is a public announcement from a company regarding the repurchase and cancellation of restricted shares related to equity incentives, which will reduce the company's registered capital. It includes details about the repurchase plan, the reduction in registered capital, and a creditor notification period for claims. The document is not a financial report, earnings release, or management discussion. It is a formal announcement related to a capital change due to share repurchase and cancellation. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length is short and it is not announcing the publication of a report but is itself the announcement of a capital change event.
2016-01-18 Chinese
简式权益变动报告书
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report." It details the reduction in shareholding by an information disclosure obligor (天津开发区德源投资发展有限公司) in the listed company 中源协和细胞基因工程股份有限公司. The document includes specifics about the shareholding changes, dates, quantities, and the nature of the transaction (large block trades). It also references relevant Chinese securities laws and regulations governing equity changes and disclosures. This type of document is a notification of changes in significant share ownership levels, which matches the definition of Major Shareholding Notification (Code: MRQ). The document is not an annual report, earnings release, or any other financial report but a regulatory disclosure about shareholding changes.
2016-01-15 Chinese
关于召开2016年第一次临时股东大会的提示性公告
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed announcement about the convening of the 2016 first extraordinary general meeting (临时股东大会) of the company 中源协和细胞基因工程股份有限公司. It includes information about the meeting date, voting methods (including online voting), agenda items to be discussed, shareholder eligibility, registration procedures, and proxy authorization. There is no financial data or report content, but rather a notice and instructions related to the shareholder meeting. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings. The document is not a report itself, nor a voting result announcement, but a preparatory notice for the meeting and voting process.
2016-01-14 Chinese
2016年第一次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as materials for the "2016 First Extraordinary General Meeting" of Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. It contains detailed agenda, voting procedures, and a specific proposal regarding the company's provision of external guarantees to related parties, which is a typical subject for shareholder meetings. The document includes meeting rules, voting results announcement procedures, and legal opinions related to the meeting. It is not a financial report, earnings release, or management discussion but rather the official meeting materials for a shareholder meeting. Therefore, it fits the category of AGM Information (AGM-R). The document length (6228 characters) and content confirm it is the meeting materials themselves, not just an announcement of a meeting or report publication.
2016-01-11 Chinese
关于控股股东进行股票质押式回购交易的公告
Transaction in Own Shares Classification · 95% confidence The document is a public announcement regarding a stock pledge transaction by the controlling shareholder. It details the number of shares pledged, the purpose of the pledge, and associated risks. There is no financial report, earnings data, or management discussion. The content fits the description of a Transaction in Own Shares (POS) filing, which covers share repurchase or issuance activities, including stock pledges by shareholders.
2016-01-11 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.